No single type of cancer reliably causes folic acid deficiency on its own, but gastrointestinal cancers, liver cancer, and head and neck cancers are the malignancies most consistently linked to low folate levels. The relationship is tangled: the cancer itself can drain folate from tissue, the treatments used against it can block folate metabolism, and the lifestyle factors that raise cancer risk often deplete folate at the same time. When researchers have looked at hospitalized cancer patients, true folate deficiency turns out to be uncommon overall, but its consequences when present are serious enough that the connection deserves a closer look.
Gastrointestinal Cancers and Local Folate Depletion
Cancers of the digestive tract have the most direct route to folate depletion because they physically disrupt the tissue where folate is absorbed and used. The small intestine, especially the upper portion, is where dietary folate enters the bloodstream. Tumors that grow in or near the gut wall can impair this absorption mechanically, while the rapidly dividing cancer cells themselves consume folate to fuel their own DNA replication.
Colorectal cancer provides one of the clearest examples of localized folate theft. In a study comparing carcinoma tissue to the normal tissue directly beside it, folate levels in the tumor specimens were significantly lower than in the adjacent healthy mucosa. Adenoma tissue showed a similar trend, though the difference was borderline. Interestingly, blood folate levels in those patients were normal, meaning the depletion was happening at the tissue level even when the rest of the body appeared adequately supplied.1Elsevier / PubMed Central. Epithelial cell folate depletion occurs in neoplastic but not adjacent normal colon mucosa This matters because it suggests that a standard blood test might miss the problem entirely in someone with a growing colon tumor.
A hospital-based evaluation of cancer inpatients found that folate deficiency was significantly associated with gastrointestinal malignancies and GI surgeries, rather than being a universal feature of cancer in general.2Europe PMC. Laboratory evaluation of folate deficiency among inpatients with cancer Stomach cancers, cancers of the small bowel, and pancreatic cancers that obstruct the upper digestive tract all share this capacity to physically interfere with folate uptake. When surgeons remove portions of the GI tract as treatment, the remaining absorptive surface may be too small to maintain adequate folate levels without supplementation.
Head and Neck Cancers
Cancers of the mouth, throat, and larynx are strongly associated with low folate, though untangling cause from consequence is tricky. People who develop these cancers tend to be heavy drinkers and smokers, and both habits independently deplete folate. Alcohol interferes with folate absorption and accelerates its breakdown, while smoking increases folate turnover.
A study measuring serum folate in patients with head and neck squamous cell carcinoma found that their average folate level was roughly 5.8 ng/mL, compared with about 9.1 ng/mL in people who smoked but did not have cancer and 9.7 ng/mL in nonsmoking controls. The gap was statistically significant even after accounting for smoking, suggesting the cancer itself or its metabolic demands contribute to folate depletion beyond what tobacco and alcohol alone explain.3PubMed. Serum folate and homocysteine levels in head and neck squamous cell carcinoma
Large pooled analyses have also found that people who consume the least dietary folate face a higher risk of oral and pharyngeal cancer in the first place. One international analysis reported that those in the highest category of folate intake had about 35% lower odds of developing these cancers than those in the lowest category. The risk climbed steeply for heavy drinkers with low folate intake, who faced roughly four times the cancer risk compared with light drinkers who ate folate-rich diets.4Wiley Online Library (Int J Cancer). Folate intake and the risk of oral cavity and pharyngeal cancer: a pooled analysis within the International Head and Neck Cancer Epidemiology Consortium So the relationship runs in both directions: low folate raises the risk of the cancer, and the cancer further lowers folate.
Liver Cancer and Progressive Folate Decline
Hepatocellular carcinoma, the most common form of primary liver cancer, shows a pattern where folate levels drop in step with disease progression. A study of over 100 HCC patients found that serum folate was inversely correlated with tumor size, tumor multiplicity, and the presence of metastasis. Patients at the earliest stage of the disease had average serum folate around 24.5 nmol/L, while those at stage IV averaged about 10.3 nmol/L.5British Journal of Nutrition. Relationship between folate status and tumour progression in patients with hepatocellular carcinoma
Patients with low blood folate had markedly higher odds of advanced disease features, including a roughly sevenfold increase in the odds of having a large tumor and a roughly fourfold increase in the odds of metastasis, compared to patients with normal folate status. However, once the researchers adjusted for the severity of liver injury and tumor stage, the independent contribution of low folate faded. That suggests the folate depletion is largely a consequence of the liver damage and tumor burden, rather than an independent driver. Since the liver stores and processes folate, progressive liver destruction from cirrhosis and cancer naturally drains the body’s reserves.
Why Cancer Treatment Is Often the Bigger Culprit
While specific cancer types can lower folate through the mechanisms above, the treatments used against cancer are frequently a more potent cause of deficiency. Methotrexate, one of the oldest and most widely used chemotherapy drugs, works precisely by blocking the enzyme that converts folate into its active form. The drug was designed to exploit cancer cells’ dependence on folate for rapid division, but it inevitably hits healthy cells that also need folate, especially those lining the gut, bone marrow, and immune system.6PubMed. Folic acid deficiency in cancer therapy: a review of chemotherapy-induced malabsorption and supportive care strategies
The downstream effects of methotrexate-driven folate disruption include mouth sores, anemia, immune suppression, and reduced ability to tolerate further treatment cycles. These side effects are directly linked to folate depletion and can become severe enough to force dose reductions or treatment delays. In non-cancer settings like rheumatoid arthritis, where methotrexate is used at lower doses, folate supplements are routinely prescribed alongside the drug specifically to counter these adverse effects.7PubMed. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines
In cancer treatment, the calculus is more complicated. Doctors use leucovorin, a pre-activated form of folate, as a “rescue” agent after high-dose methotrexate. The idea is to restore folate in healthy tissues before they sustain permanent damage while the drug has already done its work against the tumor. Research in children with acute lymphoblastic leukemia has confirmed that leucovorin does restore intracellular folate pools during high-dose methotrexate therapy.8PLOS ONE. Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia The catch is that the rescue may also protect some tumor cells from the drug, a phenomenon researchers call “overrescue.” Timing the rescue correctly is a constant balancing act.
Childhood Leukemia and the Cost of Deficiency During Treatment
The stakes of folate deficiency during cancer treatment are especially stark in children being treated for acute lymphoblastic leukemia. A study of 52 children undergoing maintenance chemotherapy found that more than half developed folate deficiency at some point during treatment. The deficient children fared substantially worse: they experienced significantly higher rates of dangerously low blood counts, febrile episodes, and the need for chemotherapy dose reductions. Most troublingly, deaths during the maintenance phase were higher in the folate-deficient group, with eight deaths among 29 deficient children compared to just one among 23 children with adequate folate levels.9PubMed. Folate deficiency in north Indian children undergoing maintenance chemotherapy for acute lymphoblastic leukemia-Implications and outcome
This finding complicates the widespread assumption that folate supplementation should be withheld during cancer treatment to avoid helping tumors grow. In childhood ALL, the maintenance phase uses methotrexate specifically because it disrupts folate metabolism in leukemia cells. But if the resulting whole-body folate depletion is severe enough to increase mortality from infections and bone marrow failure, the treatment may be undermining itself. Monitoring folate status during chemotherapy, and cautiously supplementing when levels are critically low, may improve survival rather than hinder it.
Cancers That Consume Extra Folate Through Receptor Overexpression
Some cancer types deplete folate through a less obvious route: they ramp up production of folate receptors on their cell surfaces, pulling in far more folate than normal tissue would. The best-studied of these receptors, called folate receptor alpha, is heavily overexpressed in several solid tumor types, most notably ovarian cancer, non-small-cell lung cancer, and colon cancer.10Europe PMC / International Journal of Molecular Sciences. Folate Receptor Alpha-A Novel Approach to Cancer Therapy
This overexpression is a double-edged sword. On one hand, the tumor’s appetite for folate contributes to depriving surrounding tissue of the nutrient. On the other hand, that very appetite has become a target for drug designers. Researchers have developed cancer drugs that are chemically attached to folate molecules, essentially using folate as bait to deliver toxic payloads directly into cancer cells that are greedily absorbing it. Ovarian cancer has been the primary testing ground for these folate-targeted therapies because the receptor overexpression there is especially pronounced and consistent.
For the patient, the practical implication is that cancers with high folate receptor expression may silently drain local and circulating folate, especially when tumor burden is large. This can show up as megaloblastic changes in blood cells or as subtle neurological symptoms before anyone connects the dots to the underlying malignancy.
How Common Is True Folate Deficiency in Cancer Patients?
Despite the many pathways linking cancer to low folate, outright folate deficiency in cancer patients is rarer than you might expect, at least in countries with folate-fortified food supplies. When one hospital systematically evaluated inpatients who had been tested for folate deficiency, only about 7% met the clinical threshold for true deficiency (a serum folate below 2.0 ng/mL). The strongest predictors were malnutrition, alcohol abuse, and GI-related cancers or surgeries, not cancer in general.2Europe PMC. Laboratory evaluation of folate deficiency among inpatients with cancer
This means that while certain cancers create conditions favorable to folate depletion, many cancer patients never develop measurable deficiency. Grain fortification programs, which add synthetic folic acid to flour and cereals, have raised baseline folate levels across entire populations and appear to provide a buffer even when disease or treatment strains folate metabolism. The patients who do develop deficiency tend to have compounding factors: poor appetite from the cancer or its treatment, chronic alcohol use, or a tumor physically located in the digestive tract.
For people who are curious about whether their cancer might be causing folate problems, the honest answer is that it depends on the specific cancer type, the extent of the disease, what treatments are being used, and their overall nutritional status. A routine blood test can check serum folate, and a complete blood count will often show the first signs of deficiency through enlarged red blood cells.
The Folic Acid Paradox in Cancer
One of the more confusing aspects of the folate-cancer relationship is that while deficiency is harmful, excess folic acid supplementation may also pose risks. The concern centers on the idea that folate fuels DNA replication, and once a cancer has already started growing, supplying extra folate could accelerate that growth. Some researchers have described folate as having a dual personality in cancer: protective before a tumor initiates, but potentially dangerous once a tumor exists.
Evidence supporting this concern comes from studies showing that very high doses of folic acid supplements during pregnancy may increase cancer risk in certain populations. One trial found that pregnant women given the highest folic acid dose (5 mg per day, which is far above the standard prenatal dose) had about 70% greater cancer risk than women given a placebo. In a separate study of mothers with epilepsy who took high-dose folic acid alongside anti-seizure medication, their children’s cancer risk was roughly threefold higher, with leukemia being the most common cancer observed.11SAGE Journals (The Journal of International Medical Research). Folic acid: friend or foe in cancer therapy
These findings are specific to very high supplemental doses, not to folate obtained from food, and they don’t apply to the standard 400-800 microgram doses used in most prenatal vitamins. But they underscore why oncologists are cautious about folate supplementation in patients with active malignancies. The clinical challenge is identifying the patients who genuinely need more folate to survive their treatment without inadvertently feeding their cancer.
The Role of Kidney Function
Folate balance depends not only on intake and absorption but also on how efficiently the kidneys reclaim folate that filters through them. Under normal conditions, the kidneys reabsorb most filtered folate and return it to the bloodstream. When kidney function is impaired, whether from cancer itself, chemotherapy-related kidney damage, or a pre-existing condition, folate losses in the urine increase.12Europe PMC / Nutrients. Renal Reabsorption of Folates: Pharmacological and Toxicological Snapshots
Renal cell carcinoma, the most common kidney cancer, can directly compromise this reabsorptive capacity. But the problem extends beyond kidney cancers. Many chemotherapy drugs are cleared through the kidneys and can damage renal tubules in the process. Cisplatin, a platinum-based drug used across a wide range of cancer types, is notorious for kidney toxicity. When kidney filtration and reabsorption are disrupted by either the tumor or the treatment, folate that would normally be recycled is instead lost in urine. In patients who are also eating poorly or absorbing folate inefficiently, renal losses can push an already strained system into clinical deficiency.